| Name | Title | Contact Details |
|---|
Global Healthcare Alliance is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Houston, TX. To find more information about Global Healthcare Alliance, please visit www.globalhca.com.
DocuMed Medical Transcriptions is a Lakewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mobile Medical Intl is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
It is hard to believe that 17 years ago, Jim and Kathy Coover founded Isagenix in partnership with John Anderson and six employees in a small office in Tempe, AZ. Today, we are the largest company by revenue headquartered in Gilbert, AZ, and the 4th largest for-profit company in AZ. We continue to gain recognition and respect for our strong business practices both nationally and internationally. Our honors have included the Better Business Bureau naming us a 2018 BBB Torch Awards for Ethics Finalist in recognition of our commitment to “do the right thing.” In addition, Jim Coover was named 2017 CEO of the Year, and in 2018 and 2019 we were named one of the Best Places to Work, one of the Healthiest Employers, and one of the Valley`s 10 Largest Corporate Philanthropists. Today our family-owned and operated business is in 14 markets, has half a million customers worldwide, and offers more than 100 life-changing products, packs, and systems!
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.